Recent News

• 12.08.2025 - Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia
• 11.19.2025 - Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease
• 11.03.2025 - Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition
• 10.30.2025 - Agios Reports Third Quarter 2025 Financial Results and Provides Business Update
• 10.17.2025 - Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia
• 10.16.2025 - Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET

Recent Filings

• 12.05.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.12.2025 - 144 Report of proposed sale of securities
• 11.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.30.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.30.2025 - 8-K Current report
• 10.30.2025 - EX-99.1 EX-99.1
• 10.30.2025 - 144 Report of proposed sale of securities